<  HOME  <  NEWS  <  PRESS RELEASES
PRESS RELEASES

2006
3/06/06 Icagen Provides Update On Status Of Enrollment in Pivotal Phase III Trial
3/03/06 Icagen Annouces Planned Retirement of Heyward Hull, Senior VP Clinical Development
3/01/06 Icagen Reports Fourth Quarter and Full Year 2005 Financial Results
2/22/06 Icagen Announces Fourth Quarter And Full Year 2005 Results Conference Call
2/08/06 Icagen to Present At The BIO CEO & Investor Conference
1/30/06 Icagen's Phase III Clinical Trial of ICA-17043 On Course Following Safety Review
1/03/06 Icagen to Present At 24th Annual JPMorgan Healthcare Conference
2005
12/22/05 Icagen Provides Update on Atrail Fibrillation Program
12/02/05 Icagen Expands Management Team
11/23/05 Icagen To Present At The CIBC Best Ideas Small & Mid Cap Conference
11/22/05 North Carolina Technology Association (NCTA) Names Icagen The Healthcare/Pharmaceutical Company of the Year
11/04/05 Icagen Reports Third Quarter 2005 Financial Results
11/01/05 Icagen To Present At Two Upcoming Conferences
10/27/05 Icagen Announces Third Quarter 2005 Financial Results Conference Call
10/19/05 Icagen Reports Results Of Phase II Open Label Extension Study of ICA-17043
10/18/05 Icagen To Present At The 2005 BIO Investor Forum
10/14/05 Icagen Announces Appointment of Charles A. Sanders as Chairman of Board
8/09/05 Icagen Reports Second Quarter 2005 Financial Results
8/02/05 Icagen Announces Second Quarter 2005 Financial Results Conference Call
5/17/05 Icagen To Present At The Annual UBS Global Pharmaceuticals Conference
5/13/05 Icagen Reports First Quarter 2005 Financial Results
3/30/05 Icagen Reports Fourth Quarter And Full Year 2004 Financial Results And Reports Results Of Phase Ib Clinical Trial Of ICA-69673
3/30/05 Icagen To Present At The Annual Cibc Biotechnology & Specialty Pharmaceuticals Conference
3/16/05 Icagen Announces The Appointment Of Martin Simonetti To The Company's Board Of Directors
3/15/05 Icagen Receives Milestone Payment From Yamanouchi Pharmaceutical Co., Ltd.
3/10/05 Icagen Announces Underwriters' Purchase Of 100,000 Shares Of Common Stock Pursuant To Over-Allotment Option
2/22/05 Icagen Initiates Enrollment in Pivotal Phase III Trial of
ICA-17043 for the Treatment of Sickle Cell Disease
2/03/05 Icagen, Inc. Announces Its Initial Public Offering
1/14/05 Icagen And Abbott Renew Drug Discovery Collaboration
2004
12/6/04 Icagen Reports Positive Results of Phase II Clinical Trial of ICA-17043 for the Treatment of Sickle Cell Anemia
9/1/04 Icagen Receives Milestone Payment From McNeil Consumer & Specialty Pharmaceuticals
6/29/04 Icagen And McNeil Consumer & Specialty Pharmaceuticals Enter Into Development And Commercialization Agreement For Sickle Cell Disease Treatment;
6/16/04 Icagen Expands Senior Management Team
2/2/04 Icagen Raises $19.5 Million to Advance Ion Channel Drug Discovery and Development Programs
2003
12/23/03 Icagen Initiating Phase I Clinical Development Program for ICA-69673, A Novel Drug Candidate for Epilepsy
11/20/03 Icagen and Abbott Renew Drug Discovery
09/03/03 Icagen Completes Patient Enrollment for Phase II
2002
12/20/02 Icagen and Bristol-Myers Squibb Renew Drug Discovery Collaboration
10/7/02 Icagen Announces Fast Track Status for ICA-17043
09/23/02 Icagen Presents Results of Phase Ib Clinical Trial for ICA-17043
03/29/02 Abbott Laboratories and Icagen Expand Drug Discovery Collaboration for promising Pain Target
2001
11/14/01 Icagen Expands Senior Management Team
10/22/01 Icagen and Bristol-Meyers Squibb Renew Drug Discovery and Development Collaboration
05/01/01 Icagen Expands Senior Management Team
03/27/01 Icagen Raises $23 Million to Advance Ion Channel Drug Discovery and Development Programs
03/07/01 Abbott Laboratories and Icagen Extend and Expand Drug Discovery Collaboration
2000
09/06/00 Icagen And Bristol-Myers Squibb Renew Drug Discovery Development Collaboration
08/25/00 Icagen Honored As Third Fastest Growing Technology Company In North Carolina
08/02/00 Icagen Acquires Novel Ion Channel Gene Technology and Targets for Nervous System and Immunological Disorders
03/27/00 Icagen and Yamanouchi Form Collaboration to Develop Novel Central Nervous System Therapeutics
03/22/00 Icagen and Children's Hospital Boston Collaborate to Identify and Develop Novel Pharmaceuticals
03/16/00 Icagen Appoints James Heyward Hull, Pharm.D., to Senior Vice President of Development and Regulatory Affairs
02/09/00 Genome Therapeutics and Icagen Collaborate to Conduct Preclinical Analysis of Drug Target in Potential Patient Populations
1999
11/30/99 Icagen Raises $19 Million to Advance Ion Channel Drug Discovery and Development Programs
10/19/99 Icagen Acquires Ion Channel Technology from Axys Pharmaceuticals
10/13/99 Rhone-Poulenc Agro and Icagen Initiate Chemistry and Screening Agreement
08/03/99 Icagen and Bristol-Myers Squibb Extend Drug Discovery and Development Collaboration
06/24/99 Icagen Obtains Exclusive Rights to Ion Channel Disease Targets from the Research Foundation of State University of New York's Stony Brook Campus
02/10/99 Incyte and Icagen Announce Collaborative Agreement in Ion Channel Research
01/12/99 Icagen Obtains Exclusive Rights to Novel Ion Channel Drug Discovery Technology from Rockefeller University
1998
04/28/98 Icagen Issued Four Key Patents on Novel Ion Channel Drug Discovery Technology
02/27/98 Icagen Issued Two Key Patents on Novel Ion Channel Drug Discovery Technology
1997
12/08/97 Icagen Announces Ion Channel Research Collaboration With Abbott Laboratories
11/04/97 Icagen Awarded $590,000 Phase II SBIR Grant to Continue Work on Functional Assays for Ion Channel Drug Targets
09/30/97 Bristol-Myers Squibb and Icagen Initiate Ion Channel Collaboration
08/15/97 Icagen Appoints Dr. Dennis Gillings to Board of Directors
06/18/97 Icagen Appoints Dr. Charles A. Sanders to Board of Directors
05/14/97 Icagen Raises $5,700,000 In Private Placement


Next: Press Contacts




 Contact Us     Directions      Site Map Copyright © Icagen, Inc.   All rights reserved